- Home
- BHVN
BHVN
Biohaven Ltd.
as 02-21-2025 4:00pm EST
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 4.2B | IPO Year: | 2017 |
| Target Price: | $63.15 | AVG Volume (30 days): | 725.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.80 - $62.21 | Next Earning Date: | 03-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 154.39% |
Stock Insider Trading Activity of Biohaven Ltd. (BHVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| CHILDS JOHN W | BHVN | Director | Dec 30 '24 | Buy | $35.94 | 29,000 | $1,042,393.40 | 2,368,741 |
Latest Biohaven Ltd. News
BHVN Breaking Stock News: Dive into BHVN Ticker-Specific Updates for Smart Investing
Motley Fool
11 days ago
Why Biohaven Stock Triumphed on Tuesday
Investor's Business Daily
11 days ago
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines
Insider Monkey
11 days ago
Why Biohaven (BHVN) Stock Is Rallying Today
PR Newswire
11 days ago
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
The Wall Street Journal
a month ago
Pfizer to Pay $60 Million in Kickback, False Claims Settlement
PR Newswire
a month ago
Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy
GlobeNewswire
a month ago
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
PR Newswire
a month ago
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Compare BHVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BHVN Biohaven Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.